 Rebecca Scalzo
Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 10 | 2023 | 2518 | 1.390 |
Why?
| | Cardiorespiratory Fitness | 2 | 2019 | 55 | 1.160 |
Why?
| | Exercise | 9 | 2022 | 2043 | 0.830 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 68 | 0.720 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2021 | 161 | 0.680 |
Why?
| | Physical Endurance | 3 | 2015 | 275 | 0.640 |
Why?
| | Hypoxia | 3 | 2015 | 1112 | 0.630 |
Why?
| | Mitochondria, Muscle | 3 | 2018 | 116 | 0.620 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 33 | 0.620 |
Why?
| | Leg | 1 | 2021 | 236 | 0.610 |
Why?
| | Diastole | 1 | 2019 | 149 | 0.600 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.600 |
Why?
| | Vascular Stiffness | 3 | 2023 | 493 | 0.600 |
Why?
| | Rats, Wistar | 5 | 2024 | 455 | 0.600 |
Why?
| | Weight Gain | 1 | 2021 | 519 | 0.560 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 82 | 0.560 |
Why?
| | Sex Characteristics | 4 | 2023 | 759 | 0.550 |
Why?
| | Performance-Enhancing Substances | 1 | 2017 | 10 | 0.550 |
Why?
| | Adipose Tissue | 1 | 2021 | 630 | 0.540 |
Why?
| | Carotid Arteries | 1 | 2018 | 206 | 0.520 |
Why?
| | Venoms | 1 | 2016 | 29 | 0.520 |
Why?
| | Metformin | 2 | 2017 | 330 | 0.520 |
Why?
| | Insulin Resistance | 2 | 2023 | 1203 | 0.510 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2016 | 36 | 0.510 |
Why?
| | Aorta | 2 | 2018 | 417 | 0.510 |
Why?
| | Sympatholytics | 2 | 2015 | 15 | 0.510 |
Why?
| | Clonidine | 2 | 2015 | 28 | 0.500 |
Why?
| | Athletic Performance | 1 | 2017 | 79 | 0.500 |
Why?
| | Methazolamide | 1 | 2015 | 4 | 0.500 |
Why?
| | Aminophylline | 1 | 2015 | 10 | 0.500 |
Why?
| | Physical Conditioning, Animal | 1 | 2018 | 256 | 0.490 |
Why?
| | Adipose Tissue, White | 2 | 2024 | 41 | 0.480 |
Why?
| | Altitude | 2 | 2017 | 485 | 0.480 |
Why?
| | Oxygen Consumption | 5 | 2021 | 695 | 0.480 |
Why?
| | Adaptation, Physiological | 2 | 2018 | 549 | 0.460 |
Why?
| | Diabetic Angiopathies | 1 | 2016 | 259 | 0.450 |
Why?
| | Muscle, Skeletal | 7 | 2023 | 1710 | 0.430 |
Why?
| | Adipose Tissue, Brown | 1 | 2014 | 53 | 0.420 |
Why?
| | Fibronectins | 1 | 2014 | 133 | 0.410 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2016 | 382 | 0.410 |
Why?
| | Tamoxifen | 3 | 2023 | 202 | 0.390 |
Why?
| | Muscle Proteins | 1 | 2014 | 228 | 0.380 |
Why?
| | Obesity | 3 | 2023 | 2982 | 0.360 |
Why?
| | Running | 1 | 2014 | 230 | 0.360 |
Why?
| | Hypoglycemic Agents | 2 | 2019 | 1283 | 0.350 |
Why?
| | Peptides | 1 | 2016 | 979 | 0.340 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 193 | 0.280 |
Why?
| | Rats | 4 | 2024 | 5639 | 0.250 |
Why?
| | Exercise Tolerance | 2 | 2018 | 279 | 0.240 |
Why?
| | Male | 16 | 2023 | 67309 | 0.210 |
Why?
| | Ovariectomy | 1 | 2024 | 152 | 0.210 |
Why?
| | Sucrose | 1 | 2023 | 110 | 0.200 |
Why?
| | Double-Blind Method | 2 | 2019 | 1981 | 0.200 |
Why?
| | Follicle Stimulating Hormone | 1 | 2024 | 244 | 0.190 |
Why?
| | Exercise Test | 2 | 2015 | 625 | 0.190 |
Why?
| | Insulin | 3 | 2023 | 2406 | 0.190 |
Why?
| | Diet, High-Fat | 1 | 2023 | 247 | 0.190 |
Why?
| | Sympathetic Nervous System | 2 | 2014 | 182 | 0.190 |
Why?
| | Humans | 19 | 2023 | 136764 | 0.190 |
Why?
| | Insulins | 1 | 2022 | 37 | 0.180 |
Why?
| | Mice, Obese | 1 | 2021 | 66 | 0.180 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 53 | 0.180 |
Why?
| | Dietary Fats | 1 | 2023 | 304 | 0.180 |
Why?
| | Vasodilation | 3 | 2022 | 496 | 0.180 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 366 | 0.180 |
Why?
| | Thinness | 1 | 2021 | 91 | 0.180 |
Why?
| | Female | 13 | 2024 | 72787 | 0.180 |
Why?
| | Cardiovascular Diseases | 2 | 2023 | 2104 | 0.170 |
Why?
| | Estradiol | 1 | 2024 | 518 | 0.170 |
Why?
| | Glucose | 3 | 2022 | 1019 | 0.170 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 269 | 0.170 |
Why?
| | Vasoconstriction | 2 | 2018 | 202 | 0.170 |
Why?
| | Animals | 9 | 2024 | 36823 | 0.170 |
Why?
| | Breast Neoplasms | 2 | 2023 | 2234 | 0.160 |
Why?
| | Vascular Diseases | 1 | 2022 | 243 | 0.160 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 48 | 0.150 |
Why?
| | Placebos | 1 | 2019 | 199 | 0.150 |
Why?
| | Adult | 8 | 2021 | 37630 | 0.150 |
Why?
| | Pterins | 1 | 2018 | 8 | 0.150 |
Why?
| | Cancer Survivors | 1 | 2023 | 280 | 0.150 |
Why?
| | Energy Metabolism | 1 | 2024 | 919 | 0.140 |
Why?
| | Mitochondria, Heart | 1 | 2018 | 100 | 0.140 |
Why?
| | Glycogen | 1 | 2017 | 55 | 0.140 |
Why?
| | Ventricular Fibrillation | 1 | 2017 | 60 | 0.130 |
Why?
| | Blood Vessels | 1 | 2018 | 187 | 0.130 |
Why?
| | Young Adult | 5 | 2015 | 13129 | 0.120 |
Why?
| | Oxyhemoglobins | 1 | 2015 | 23 | 0.120 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2016 | 133 | 0.120 |
Why?
| | Healthy Volunteers | 1 | 2015 | 199 | 0.120 |
Why?
| | Endothelium, Vascular | 2 | 2022 | 926 | 0.110 |
Why?
| | Seals, Earless | 1 | 2014 | 5 | 0.110 |
Why?
| | Arteries | 1 | 2016 | 269 | 0.110 |
Why?
| | Diving | 1 | 2014 | 4 | 0.110 |
Why?
| | Deuterium Oxide | 1 | 2014 | 16 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 703 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2021 | 1314 | 0.110 |
Why?
| | Physical Education and Training | 1 | 2014 | 76 | 0.110 |
Why?
| | Physical Conditioning, Human | 1 | 2014 | 41 | 0.100 |
Why?
| | Aged | 5 | 2022 | 23794 | 0.100 |
Why?
| | Oxygen | 1 | 2018 | 930 | 0.100 |
Why?
| | Cell Respiration | 3 | 2018 | 102 | 0.100 |
Why?
| | Fibroblast Growth Factors | 1 | 2014 | 171 | 0.100 |
Why?
| | Blood Pressure | 2 | 2021 | 1774 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1062 | 0.100 |
Why?
| | Quadriceps Muscle | 1 | 2014 | 132 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 256 | 0.090 |
Why?
| | Heart Ventricles | 1 | 2016 | 785 | 0.090 |
Why?
| | Heart Rate | 1 | 2015 | 820 | 0.090 |
Why?
| | Blood Glucose | 2 | 2019 | 2181 | 0.090 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5735 | 0.090 |
Why?
| | Middle Aged | 3 | 2019 | 33228 | 0.070 |
Why?
| | Mice | 2 | 2021 | 17733 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5106 | 0.070 |
Why?
| | Ovary | 1 | 2024 | 221 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2022 | 240 | 0.050 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2021 | 29 | 0.050 |
Why?
| | Longevity | 1 | 2022 | 164 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 267 | 0.040 |
Why?
| | Transgenes | 1 | 2021 | 179 | 0.040 |
Why?
| | Glutathione | 1 | 2022 | 356 | 0.040 |
Why?
| | Estrogens | 1 | 2023 | 367 | 0.040 |
Why?
| | Body Composition | 1 | 2024 | 679 | 0.040 |
Why?
| | Body Weight | 1 | 2024 | 985 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 621 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 557 | 0.040 |
Why?
| | Carbohydrates | 1 | 2018 | 65 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 665 | 0.040 |
Why?
| | Transcriptome | 1 | 2024 | 969 | 0.030 |
Why?
| | Citrate (si)-Synthase | 1 | 2017 | 60 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2022 | 915 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 364 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 155 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2160 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 197 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 2017 | 262 | 0.030 |
Why?
| | Liver | 1 | 2024 | 1940 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2017 | 487 | 0.030 |
Why?
| | Swine | 1 | 2017 | 773 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2018 | 436 | 0.030 |
Why?
| | Mitochondria | 1 | 2018 | 946 | 0.020 |
Why?
| | Fatty Acids | 1 | 2014 | 442 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1059 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1758 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 5075 | 0.010 |
Why?
| | Adolescent | 1 | 2022 | 21382 | 0.010 |
Why?
|
|
Scalzo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|